Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1A/1B, Two-Stage Study of a PSA/IL-2/GM-CSF Vaccine for the Treatment of PSA Recurrent Prostate Cancer in Hormone-Naive and Hormone-Independent Patients

Next Previous
X
Search
Trial Profile

A Phase 1A/1B, Two-Stage Study of a PSA/IL-2/GM-CSF Vaccine for the Treatment of PSA Recurrent Prostate Cancer in Hormone-Naive and Hormone-Independent Patients

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PSA-IL2-GM-CSF vaccine (Primary) ; Interleukin-2
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Oncobioimune; Theralink Technologies

    • Most Recent Events

    • 09 Jan 2019 According to an OncBioMune Pharmaceuticals media release, the company now collecting long-term follow-up results for the 1a portion of this trial.
    • 07 Sep 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 02 Jul 2018 According to an OncBioMune Pharmaceuticals media release, company is collecting long-term follow-up results for the 1a portion of this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top